Aldara News and Research

RSS
Aldara (imiquimod) is a synthetic agent with immune response modifying activity. As an immune response modifier (IRM), imiquimod stimulates cytokine production, especially interferon production, and exhibits antitumor activity, particularly against cutaneous cancers. Imiquimod's proapoptotic activity appears to be related to Bcl-2 overexpression in susceptible tumor cells. Check for active clinical trials or closed clinical trials using this agent.
Meda publishes 2009 year-end report

Meda publishes 2009 year-end report

Health Canada approves Zyclara Cream for multiple actinic keratoses

Health Canada approves Zyclara Cream for multiple actinic keratoses

Graceway Pharmaceuticals acquires global rights to Gilead Sciences' GS 9191 anti-proliferative agent

Graceway Pharmaceuticals acquires global rights to Gilead Sciences' GS 9191 anti-proliferative agent

National campaign to raise awareness of actinic keratosis

National campaign to raise awareness of actinic keratosis

Anadys Pharmaceuticals presents data showing ANA773 promotes anti-tumor activity of killer cells

Anadys Pharmaceuticals presents data showing ANA773 promotes anti-tumor activity of killer cells

New cream treatment for common form of skin cancer

New cream treatment for common form of skin cancer

3M granted FDA approval for cream to treat superficial basal cell carcinoma

3M granted FDA approval for cream to treat superficial basal cell carcinoma

FDA approval for skin cancer cream

FDA approval for skin cancer cream